Andréas Mackensen

← Back to Friedrich-Alexander-Universität Erlangen-Nürnberg

ORCID

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

1. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells

   2016 · 2,013 citations

2. Inhibitory effect of tumor cell–derived lactic acid on human T cells

   2007 · 1,935 citations

3. CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up

   2024 · 1,095 citations

4. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

   2022 · 1,092 citations

5. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression

   2005 · 728 citations

6. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

   2004 · 637 citations

7. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus

   2021 · 610 citations

8. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

   2006 · 505 citations

9. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

   2021 · 475 citations

10. CAR T-cell therapy in autoimmune diseases

    2023 · 430 citations

11. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

    2016 · 428 citations

12. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

    2015 · 401 citations

13. Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance

    2004 · 361 citations

14. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells

    2000 · 345 citations

15. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells

    2003 · 306 citations

16. Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro

    2006 · 297 citations

17. Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma

    2006 · 297 citations

18. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

    2023 · 297 citations

19. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

    2018 · 295 citations

20. Isolation and characterization of human antigen-specific TCRαβ+ CD4-CD8- double-negative regulatory T cells

    2004 · 266 citations

21. CD19-targeted CAR T cells in refractory antisynthetase syndrome

    2023 · 260 citations

22. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    2019 · 257 citations

23. Advancements and challenges in CAR T cell therapy in autoimmune diseases

    2024 · 252 citations

24. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs

    2014 · 251 citations

25. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    2019 · 248 citations

← Return to the university profile